Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Oncotarget|September 28, 2014
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitorsBurhan Hassan, Argun Akcakanat, Takafumi Sangai, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 27, 2014
Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathwayElvin Blanco, Takafumi Sangai, Suhong Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive CancerMing Zhao, Stephen Scott, Kurt W Evans, et al.
JCI Insight|December 27, 2016
Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapyJiha Kim, Pedro Correa de Sampaio, Donna Marie Lundy, et al.
Scientific Reports|January 25, 2022
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterationsSeyed Pairawan, Argun Akcakanat, Scott Kopetz, et al.
Molecular Cancer Therapeutics|April 29, 2025
Efficacy of ATR kinase inhibitor elimusertib monotherapy or combination in tumors with DNA damage response pathway and other genomic alterationsKaushik Varadarajan, Christian X Cruz Pico, Kurt W Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2023
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing CancersTimothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, et al.
Scientific Reports|November 19, 2023
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancerTurcin Saridogan, Argun Akcakanat, Ming Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2017
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type TumorsKurt W Evans, Erkan Yuca, Argun Akcakanat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2024
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft ModelsFunda Meric-Bernstam, Erkan Yuca, Kurt W Evans, et al.
Pageof 4